AzTrials
AzTrials

Refractory Solid TumorsEarly Phase 1NCT06150365

Personalized KSX01-TCRT in Patients With Advanced Solid Tumors

A Early Phase 1 study testing KSX01-TCRT cell therapy in people with Refractory Solid Tumors and Relapsed Solid Tumors, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences at 1 site in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This trial is a single arm, open phase I clinical study to investigate the safety and efficacy of personalized KSX01-TCRT in patients with advanced solid tumors. This experiment is divided into two parts: the dose increasing stage (Part A) and the dose expanding stage (Part B). Read more about this study

Who is it for?
Ages 18 to 70 years
What is being tested?
KSX01-TCRT cell therapy
Could I receive a placebo?
No, everyone receives an active treatment
How many people
12 participants
Where
1 siteChina
Study dates
7 Nov 2023to 1 Dec 2028
Phase
Early Phase 1
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Screening period 1- inclusion criteria:
  • Patients should complete all examinations for screening period 1 within 28 days after signing the informed consent form. Only those who meet the inclusion criteria for this stage can collect fresh tumor tissue, 2-3 archived pathological tissue white slides, and peripheral blood for TCR sequence screening and HLA typing testing.
  • Volunteer to participate in clinical research; Fully understand this study and voluntarily sign an informed consent form; Willing to follow and capable of completing all testing procedures.
  • Age range from 18 to 70 years old (including boundary values).
  • Solid tumors that have been confirmed by histological or cytological evaluation as incurable or metastatic, and have failed standard treatment or currently have no available standard treatment.
  • Expected survival time>6 months.
Show all 32Show fewer
  • ECOG score 0 or 1.
  • Having sufficient organ function, defined as follows:
  • 6.1) Hematology: 6.1.1) Hemoglobin 90 g/L (no blood transfusion received within 14 days prior to examination); 6.1.2) Absolute value of neutrophils 1.5 109/L (did not receive granulocyte colony stimulating factor treatment within 14 days prior to examination); 6.1.3) Platelet count is 100 109/L in the absence of obvious liver lesions (primary or metastatic) (platelet transfusion not received within 14 days before examination), or 75 109/L in the presence of liver lesions (platelet transfusion not received within 14 days before examination); 6.1.4) Absolute lymphocyte count (ALC) 0.7 109/L; 6.2) Liver function: 6.2.1) Total bilirubin (TBIL) ≤ 1.5 in the absence of obvious liver lesions (primary or metastatic) × Upper limit of normal (ULN), subjects with liver lesions or Gilbert disease ≤ 3 × ULN; 6.2.2) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN (liver metastasis or liver cancer subjects can be ≤ 5 × ULN); Alkaline phosphatase (ALP) ≤ 2.5 × ULN (bone metastasis subject, ALP ≤ 5) × ULN); 6.3) Renal function: Creatinine clearance rate ≥ 60 mL/min (Cockcroft Fault formula: [140 age] × Weight [kg] × [0.85, female only]/(72 × Creatinine (mg/dl);
  • Subjects with a creatinine clearance rate of<60 mL/min but ≥ 50 mL/min can also be enrolled if all of the following conditions are met:
  • Serum creatinine and blood urea nitrogen (BUN) are within the normal range of the research center No clinical evidence showing chronic renal dysfunction (such as acidosis or electrolyte disorders) The urine routine and urine output are within the normal range of the research center Note: It is not recommended to use IL-2 during the treatment period for subjects with a baseline creatinine clearance rate of<60 mL/min.
  • The patient's HLA-I class molecule IHC expression is positive.
  • Patients with tumor lesions that can be collected and can screen out TCR sequences that can be used as drugs can enter the study. If the patient has obtained personalized TCR sequences using previously collected and archived tumor tissue in other studies, they can directly enter screening period 2, but the collection time of the archived tissue should be within one year before signing the informed consent for this study.
  • The patient agrees to receive peripheral monocyte collection after all tests in screening period 1 meet the standards.
  • Screening period 2- inclusion criteria:
  • After receiving confirmation notification of TCR sequence locking from the partner, or if the patient has obtained their personalized TCR sequence in other studies, they can be arranged to undergo various inclusion evaluations in screening period 2.
  • The organ function and key examination items of the patient at this stage should not have significant changes compared to the examination results in screening period 1. If the patient's examination results during screening period 2 exceed the following criteria, peripheral monocyte collection should not be performed until the abnormal items return to normal range.
  • Screening period 2- Routine inclusion criteria
  • Confirmed screening and locking of tumor specific TCR sequences from the patient's own body. For patients who have obtained TCR sequences through other research projects, they should sign an informed consent form for this research project before entering screening period 2.
  • Expected survival time>6 months.
  • ECOG score 0 or 1.
  • Having sufficient organ function, defined as follows:
  • 4.1) Hematology: 4.1.1) Hemoglobin 90 g/L (no blood transfusion received within 14 days prior to examination); 4.1.2) Absolute value of neutrophils is 1.0 109/L (did not receive granulocyte colony stimulating factor treatment within 14 days before the examination); 4.1.3) Platelet count is 75 109/L in the absence of obvious liver lesions (primary or metastatic) (platelet transfusion was not received within 14 days before the examination); 4.1.4) Absolute lymphocyte count (ALC) 0.7 109/L; 4.2) Liver function: 4.2.1) Total bilirubin (TBIL) ≤ 1.5 in the absence of obvious liver lesions (primary or metastatic) × Upper limit of normal (ULN), subjects with liver lesions or Gilbert disease ≤ 3 × ULN; 4.2.2) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN (liver metastasis or liver cancer subjects can be ≤ 5 × ULN); Alkaline phosphatase (ALP) ≤ 2.5 × ULN (bone metastasis subject, ALP ≤ 5) × ULN); 4.3) Renal function: Creatinine clearance rate ≥ 60 mL/min (Cockcroft Fault formula: [140 age] × Weight [kg] × [0.85, female only]/(72 × Creatinine (mg/dl);
  • Subjects with a creatinine clearance rate of<60 mL/min but ≥ 50 mL/min can also be enrolled if all of the following conditions are met:
  • Serum creatinine and blood urea nitrogen (BUN) are within the normal range of the research center No acidosis or electrolyte disorders The urine routine and urine output are within the normal range of the research center Note: It is not recommended to use IL-2 during the treatment period for subjects with a baseline creatinine clearance rate of<60 mL/min.
  • 4.4) The patient naturally breathes (without assisted oxygen supply) with a basal blood oxygen saturation of>92%.
  • Agree to accept peripheral monocyte collection. 6) Women of childbearing age who have the ability to conceive have a negative blood pregnancy test within 7 days before the first cell infusion (non fertility: surgical sterilization or at least 2 years after menopause), and the subjects of childbearing age use medically recognized contraceptive measures from the start of research treatment (chemotherapy) to 5 months after the last cell infusion, and no eggs have been retrieved during this period.
  • 7) Male participants are willing to take medically approved contraceptive measures within 5 months after signing the informed consent form and the last cell infusion, and do not donate sperm during this period.
  • 8) According to the iRECIST standard, there is at least one measurable lesion present. The following situations require approval from the researcher:
  • During the dose increasing stage, subjects only have evaluable lesions but can evaluate their efficacy through their serum tumor markers;
  • The subjects currently do not have measurable lesions, but the researchers have determined that they may develop or become measurable lesions within one month.
  • 9) The toxicity and adverse reactions caused by frontline treatment should be restored to Grade 1 (excluding clinically insignificant toxicity, such as hair loss caused by chemotherapy).

Who cannot join

  • Screening period 1- Exclusion criteria:
  • Subjects who meet any of the following criteria shall not participate in this clinical study:
  • The patient has received systemic chemotherapy on line 3 or above:
  • Patients can be enrolled during the first line systemic chemotherapy, during the second line systemic chemotherapy period, or after the end of the second line systemic chemotherapy (enrollment time is screening period 2 and meets the standards and receives clearance chemotherapy), but they cannot receive the third line systemic chemotherapy before enrollment:
  • The second and third line systemic chemotherapy is defined as a systematic chemotherapy regimen after the progression of frontline treatment;
  • For patients who complete neoadjuvant chemotherapy in the early stage of their disease, their neoadjuvant chemotherapy regimen can include up to two types of chemotherapy;
Show all 43Show fewer
  • For patients who meet all other inclusion criteria but have a large number of frontline treatment lines, they can also be included after evaluation and confirmation by the researchers.
  • Frontline treatment plans targeting biological agents (such as immune checkpoint inhibitors), small molecule targeted drugs, etc., are not considered as exclusion criteria.
  • Within two years before signing the informed consent, the patient had a medical history of other malignant tumors, except for non melanoma skin cancer, some cancers in situ (such as cervical cancer, bladder cancer, breast cancer), or low-risk prostate cancer.
  • Clinically confirmed liver diseases, including active hepatitis virus infection, alcoholic hepatitis, other types of hepatitis, cirrhosis, and hereditary liver diseases; Among them, the subject's
  • Hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb) are positive, and the hepatitis B virus DNA (HBV DNA) in the peripheral blood is higher than the lower detection limit of the research center;
  • HCV-Ab positive and HCV-RNA above the lower detection limit of the research center Patients who can effectively control HBV-DNA and/or HCV-RNA after treatment can also be included in the group after being evaluated and approved by the researcher. HBV-DNA positive subjects should receive hepatitis B treatment after signing the informed consent form and continue to receive KSX01-TCRT infusion for at least 6 months. Such subjects should also monitor their HBV-DNA and hepatitis B related antigen antibodies on Day28 and at each follow-up visit point.
  • History of myocardial infarction, history of cardiac bypass surgery, unstable angina, active atrial fibrillation requiring treatment, symptomatic sinus bradycardia (heart rate<50 beats/min), or other clinically significant heart diseases within 6 months prior to signing the informed consent form.
  • Tumor lesions invading the heart or large blood vessels. The patient has permanent percutaneous nephrostomy, catheterization, bile duct, and other indwelling tubes, except for those that the researchers believe can be removed before gonorrhea clearance.
  • 7) Primary immune deficiency. 8) HIV positive; Active HBV or HCV infection. 9) Received allogeneic stem cell transplantation within 6 months before signing the informed consent form.
  • 10) Prior to signing the informed consent form, CAR T cell therapy or other genetically modified T cell therapy other than this research technique was received.
  • 11) Known allergies to dimethyl sulfoxide (DMSO) or any other cellular formulation components and potential therapeutic drugs used during treatment (such as cyclophosphamide, fludarabine, and tolumab).
  • 12) History of autoimmune diseases, except for the following:
  • -A history of hypothyroidism and the use of stable thyroid hormone replacement therapy;
  • -Patient has controllable type 1 diabetes 13) The patient's illness or condition results in their lack of understanding, participation, and/or adherence to this study plan.
  • 14) Any other disease that researchers believe will impair the subject's tolerance to the treatment regimen or significantly increase the risk of complications.
  • 15) Known history of alcohol abuse, psychotropic substance abuse, or drug use. 16) Have a clear history of neurological or mental disorders in the past, such as epilepsy, dementia, schizophrenia, etc.
  • 17) According to the judgment of the researchers, the underlying condition of the subjects may increase their risk of receiving investigational drug treatment, or may cause confusion in the interpretation of toxic reactions and adverse events that may occur.
  • Other researchers believe that it is not suitable to participate in this study.
  • Screening Period 2- Exclusion Criteria
  • Subjects who meet any of the following criteria shall not undergo peripheral monocyte collection:
  • Before monotherapy, the subject's anti-tumor treatment was not fully eluted (2 weeks or 5 half-lives, whichever is shorter):
  • -Except for the following situations: Gonadotropin (GnRH) agonists or antagonists used for the treatment of prostate cancer Hormone replacement therapy or oral contraceptives.
  • Known primary central nervous system (CNS) malignant tumors or symptomatic CNS metastases.
  • If the patient is diagnosed with a central nervous system disease and meets the following conditions with the consent of the main researcher, it is not considered an exclusion item:
  • There are measurable or evaluable lesions outside the CNS;
  • No history of intracranial or spinal cord bleeding;
  • There is no need for ongoing or planned corticosteroid treatment within 14 days prior to enrollment;
  • Receiving stable doses of anticonvulsants;
  • No stereotactic radiation or whole brain radiation therapy was received within 14 days prior to enrollment.
  • Women during pregnancy or lactation.
  • Receiving or planning to receive systemic corticosteroid therapy (>5 mg of prednisone or equivalent treatment medication per day) or immunosuppressive drugs within 7 days prior to monotherapy, except for the following:
  • Intranasal, inhalation, topical steroids, or local administration (such as intra articular injection);
  • Physiological doses of systemic steroids as an alternative therapy (such as physiological corticosteroid replacement therapy for adrenal or pituitary dysfunction);
  • Steroids are used as prophylactic drugs for hypersensitivity reactions (such as computed tomography [CT] prophylactic drugs).
  • The first second forced expiratory volume (FEV1)/forced vital capacity (FVC)<70% during lung function examination indicates abnormal lung function.
  • According to the judgment of the researchers, the underlying condition of the subjects may increase their risk of receiving investigational drug treatment, or may cause confusion in the interpretation of toxic reactions and adverse events that may occur.
  • There are severe infections within 2 weeks before single collection. Major surgery (excluding diagnostic surgery) is performed within 4 weeks prior to single collection, or is expected to be performed during the study period. Subjects can be enrolled in planned or ongoing minor surgical procedures, such as establishing venous channels.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

clinical trials ksh contact

18994103369

ksh-clinicalt@tcrximmune.com

China1 site, 1 recruiting

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    Beijing

    Ning Li

    Ning Li

    Recruiting

Other trials in China

About this study

Official title: Single Arm Clinical Study on the Safety and Efficacy of Personalized KSX01-TCRT in Patients With Advanced Solid Tumors

This trial is a single arm, open phase I clinical study to investigate the safety and efficacy of personalized KSX01-TCRT in patients with advanced solid tumors. This experiment is divided into two parts: the dose increasing stage (Part A) and the dose expanding stage (Part B). For those enrolled in the planned expansion phase, the dose should have passed the safety assessment during the dose escalation phase.

Being tested
KSX01-TCRT cell therapy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • KSX01-TCRT cell therapyBiological

    Patient autologous T cell therapy

Study groups in NCT06150365
Study groupRoleWhat they receive
TCR-T cellsExperimentalKSX01-TCRT cell therapy
Receives: Biological: KSX01-TCRT cell therapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Subject safety

    Number of participants with treatment-related adverse events assessed by CTCAE v4.0.

    Measured: about 2 years

  2. tumor efficacy

    Changes in overall tumor diameter.

    Measured: about 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Nov 2023
  2. Study start7 Nov 2023
  3. Primary completion1 Dec 2026 (estimated)
  4. Study completion1 Dec 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
KSX01-TCRT cell therapy
Masking
None (open label)
Enrolment
12 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06150365
Sponsor's protocol ID
KSX01-R08-102
Status last verified
Mar 2025
First submitted
21 Nov 2023
Last updated
26 Mar 2025
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing KSX01-TCRT cell therapy in people with Refractory Solid Tumors and Relapsed Solid Tumors, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 32 inclusion and 43 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 26 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact clinical trials ksh (18994103369, ksh-clinicalt@tcrximmune.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Subject safety (time frame: about 2 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06150365.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Mar 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in